Dengue Dilemma: Navigating Cross-Reactivity and Immune Challenges

This chapter examines the immunological mechanisms underlying the cross-reactivity and immune enhancement in dengue and how they influence the clinical outcomes. The four DENV serotypes (DENV-1 to DENV-4) share high genetic and antigenic similarity, leading to antibodies and T cells that can recognize multiple serotypes. While this cross-reactive immunity can confer partial or transient protection, it can also result in antibody-dependent enhancement (ADE), wherein non-neutralizing antibodies facilitate viral entry into immune cells, increasing the likelihood of severe disease in secondary infections and in infants carrying maternal anti-DENV antibodies. Furthermore, cross-reactivity with other flaviviruses, such as ZIKV, complicates serological diagnosis by producing false-positive results and uncertain prior exposure histories. These complexities extend to vaccine design, which must induce effective immunity against all four DENV serotypes while minimizing ADE risk. Epidemiological studies confirm that secondary infections, especially when antibody levels have waned, carry an elevated risk of severe clinical manifestations. However, the timing between infections and the specific serotype involved can modulate these outcomes. A thorough understanding of cross-reactivity and immune enhancement is therefore pivotal for advancing diagnostic accuracy, guiding patient care, and informing vaccine strategies and public health policies to better control dengue globally.